Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.64 |
| ▸ | NPC1 | O15118 | 9/20 | 0.64 |
| ▸ | RAB9A | P51151 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | CASP1 | P29466 | 2/20 | 0.64 |
| ▸ | CASP7 | P55210 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30098950 | 0.81 | KDM4E (0.59) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28167267 | 0.81 | MAPT (0.61) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3310740 | 0.80 | MEN1 (0.63) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29728201 | 0.80 | NPC1 (0.77) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL1538297 | 0.80 | NPC1 (0.77) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL11486598 | 0.80 | MEN1 (0.53) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL28218368 | 0.78 | MAPT (0.58) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL30569141 | 0.77 | NPC1 (0.73) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL29639131 | 0.77 | RAB9A (0.57) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL27022341 | 0.77 | RAB9A (0.57) | KDM4ENPC1RAB9AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1976934-B | Alkyl substituted indoloquinoxalines | OXYPHARMA AB | 2013-05-29 | — | — | CN | claimed |
| CN-1976934-A | Alkyl substituted indoloquinoxalines | OXYPHARMA AB (SE) | 2007-06-06 | — | — | CN | claimed |
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| EP-4313969-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117203199-A | N2-phenylpyrimidine-2, 4-diamine compounds, methods of making and using the same | 毕利吉生物科技股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2022-10-20 | — | — | US | disclosed |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-3210984-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-06-19 | — | — | EP | disclosed |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2018-03-15 | — | — | US | disclosed |
| US-9856274-B2 | Substituted pyrazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-02 | — | — | US | disclosed |
| CN-107141309-A | Heteroaryl compound and its application method | 桑诺维恩药品公司 | 2017-09-08 | — | — | CN | disclosed |
| US-9249162-B2 | Substituted [1,2,4]triazolo[1,5-a]pyridines as PDE-10 inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2014-09-25 | — | — | US | disclosed |
| US-8765760-B2 | [1,2,4] triazol [1,5-a] pyrazines useful as inhibitors of phosphodiesterases | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| CN-103619841-A | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC | 2014-03-05 | — | — | CN | disclosed |
| EP-2663565-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| CN-1976934-B | Alkyl substituted indoloquinoxalines | OXYPHARMA AB | 2013-05-29 | — | — | CN | disclosed |
| WO-2012096929-A2 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2012-07-12 | — | — | US | disclosed |
| CN-1976934-A | Alkyl substituted indoloquinoxalines | OXYPHARMA AB (SE) | 2007-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | KDM4E 1116/4885NPC1 2464/4885RAB9A 2821/4885 |
| US-20120178748-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | KDM4E 969/4885NPC1 458/4885RAB9A 957/4885 |
| US-20180072759-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | KDM4E 969/4885NPC1 458/4885RAB9A 957/4885 |
| US-10570156-B2 | Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors | PDE3A, PDE2A, PDE5A | KDM4E 1225/4885NPC1 1239/4885RAB9A 595/4885 |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB4 | KDM4E 1116/4885NPC1 2464/4885RAB9A 2821/4885 |
| US-20140288062-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, GPR119, NLN | KDM4E 969/4885NPC1 458/4885RAB9A 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.